Valbiotis SA

EURONEXT : ALVAL

Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

Information

Website
https://www.valbiotis.com
Sector
Healthcare
Industry
Biotechnology
Type
Common Stock
Country
France

Price

EUR 1.30

Symbol

ALVAL

Type

Common Stock

Previous Close

 :

1.30

52 Week Range

 :

1.07 - 7.50

Volume

 :

14,382.00

Average Volume

 :

47,109.00

High

 :

1.31

Low

 :

1.26

Change

 :

0.00

Percent change (%)

 :

0.31

Stakeville

A Free-to-Play Trading Game. Sharpen your skills, trade stocks, and have fun!

Play Now
Getting Started
Get Your Free Account For Educational Purpose Knowledgebase
Legal
Cookie Policy Privacy Policy Terms & Conditions
Customer Service
Help Desk Support Stakeville Newsletter
Stay Connected
Contact Us Official Blog About Us
Disclaimer: Stakeville is a simulation trading game. All trades and stock prices are fictional and do not reflect real-world markets. This game is for entertainment purposes only and does not involve real financial transactions. Read more...